The dopamine D2 and adenosine A2A receptors: Past, present and future trends for the treatment of parkinson's disease

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Herein, we present an overview of the historic development of drugs for the treatment of Parkinson s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson s disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.
Original languageEnglish
Pages (from-to)3188 - 3210
Number of pages23
JournalCurrent Medicinal Chemistry
Volume21
Issue number27
DOIs
Publication statusPublished - 2014

Cite this

@article{5399854f6c5841b28da6f9f42d5d9177,
title = "The dopamine D2 and adenosine A2A receptors: Past, present and future trends for the treatment of parkinson's disease",
abstract = "Herein, we present an overview of the historic development of drugs for the treatment of Parkinson s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson s disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.",
author = "Jorg, {Manuela Therese} and Scammells, {Peter John} and Benvenuto Capuano",
year = "2014",
doi = "10.2174/1389200215666140217110716",
language = "English",
volume = "21",
pages = "3188 -- 3210",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers",
number = "27",

}

TY - JOUR

T1 - The dopamine D2 and adenosine A2A receptors: Past, present and future trends for the treatment of parkinson's disease

AU - Jorg, Manuela Therese

AU - Scammells, Peter John

AU - Capuano, Benvenuto

PY - 2014

Y1 - 2014

N2 - Herein, we present an overview of the historic development of drugs for the treatment of Parkinson s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson s disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.

AB - Herein, we present an overview of the historic development of drugs for the treatment of Parkinson s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson s disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.

UR - http://www.eurekaselect.com/120432/article

U2 - 10.2174/1389200215666140217110716

DO - 10.2174/1389200215666140217110716

M3 - Article

VL - 21

SP - 3188

EP - 3210

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 27

ER -